首页 / 院系成果 / 成果详情页

Combined TACE with Targeted and Immunotherapy versus TACE Alone Improves DFS in HCC with MVI: A Multicenter Propensity Score Matching Study 期刊论文

编号：

335600D9EAEB2A48FDA9D431F4C612D2
作者：

Chen, Xiaokun#^[1,2]Wu, Xiangan#^[1,2]Peng, Wei^[3,4,5];Liu, Liguo(刘立国)^[6]Liu, Xiao^[1];Wan, Xueshuai^[1];Xu, Haifeng^[1];Zheng, Yongchang^[1];Zhao, Haitao^[1];Mao, Yilei^[1];Lu, Xin^[1];Sang, Xinting^[1];Chang, Xiaoyan^[7];Zhou, Kang^[8];Pan, Jie^[8];Guan, Mei^[9];Hu, Dandan^[3,4,5];Tan, Haidong(谭海东)^[6]Zhang, Yaojun*^[3,4,5]Du, Shunda*^[1]
语种：

英文
期刊：

JOURNAL OF HEPATOCELLULAR CARCINOMA ISSN：2253-5969 2025 年 12 卷 (561 - 577)
收录：
关键词：

hepatocellular carcinoma microvascular invasion postoperative adjuvant therapy targeted therapy immunotherapy transcatheter arterial chemoembolization
摘要：

Background: Hepatocellular carcinoma (HCC) with microvascular invasion (MVI) is associated with high recurrence and poor survival outcomes. Although adjuvant therapies such as transcatheter arterial chemoembolization (TACE), targeted therapy, and immunotherapy show potential in improving outcomes, the optimal postoperative treatment strategy remains undetermined. This study evaluates the efficacy of different adjuvant treatments on disease-free survival (DFS) and overall survival (OS) in HCC patients with MVI following curative resection. Methods: A retrospective cohort of 409 HCC patients with MVI who underwent curative resection from three clinical centers between 2017 and 2024 was analyzed. Patients were stratified into three groups: TACE alone (n=132), TACE + targeted therapy (n=58), and TACE + targeted immunotherapy (n=68). Propensity score matching (PSM) was employed to balance confounding factors. Kaplan-Meier survival curves and Cox regression models were used to assess DFS and OS. A nomogram was constructed for individualized DFS prediction. Results: After PSM, both the TACE + targeted therapy and TACE + targeted immunotherapy groups exhibited significantly prolonged DFS compared to TACE alone (median DFS: 16 vs 22 and 21 months, respectively; p=0.027). No significant differences were observed in OS across the groups. The nomogram for DFS demonstrated robust predictive performance, with a C-index of 0.709 and 0.645 in the training and validation cohorts, respectively, supporting its utility in clinical decision-making. Conclusion: In HCC patients with MVI, adjuvant TACE combined with targeted therapy or targeted immunotherapy significantly enhances DFS, though no OS benefit was observed. The developed nomogram provides a reliable tool for risk stratification and personalized postoperative management in this high-risk patient population.
推荐引用方式
GB/T 7714：

Chen Xiaokun,Wu Xiangan,Peng Wei, et al. Combined TACE with Targeted and Immunotherapy versus TACE Alone Improves DFS in HCC with MVI: A Multicenter Propensity Score Matching Study [J].JOURNAL OF HEPATOCELLULAR CARCINOMA,2025,12:561-577.
APA：

Chen Xiaokun,Wu Xiangan,Peng Wei,Liu Liguo,&Du Shunda.(2025).Combined TACE with Targeted and Immunotherapy versus TACE Alone Improves DFS in HCC with MVI: A Multicenter Propensity Score Matching Study .JOURNAL OF HEPATOCELLULAR CARCINOMA,12:561-577.
MLA：

Chen Xiaokun, et al. "Combined TACE with Targeted and Immunotherapy versus TACE Alone Improves DFS in HCC with MVI: A Multicenter Propensity Score Matching Study" .JOURNAL OF HEPATOCELLULAR CARCINOMA 12(2025):561-577.
入库时间：

4/2/2025 8:42:34 AM
更新时间：

4/2/2025 8:42:34 AM
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：21  下载次数：0

分享到：

浏览次数：21

下载次数：0

打印次数：0